EUVIMEDEUVIMED entdecken
Open Access

Tumor protease-activated theranostic nanoparticles for MRI-guided glioblastoma therapy

Ching-Hsin Huang, Edwin Chang, Li Zheng, Joe Gerald Jesu Raj, Wei Wu, Laura J Pisani, Heike E Daldrup-Link

Theranostics · 2023

DOI: 10.7150/thno.79342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2023. Verfasst von Ching-Hsin Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, CA, U.S.A. Hauptthemen laut MEDLINE: Glioblastoma, Nanoparticles. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

As a cancer, Glioblastoma (GBM) is a highly lethal and difficult-to-treat. With the aim of improving therapies to GBM, we developed novel and target-specific theranostic nanoparticles (TNPs) that can be selectively cleaved by cathepsin B (Cat B) to release the potent toxin monomethyl auristatin E (MMAE).

Methods

We synthesized TNPs composed of a ferumoxytol-based nanoparticle carrier and a peptide prodrug with a Cat-B-responsive linker and the tubulin inhibitor MMAE. We hypothesized that intratumoral Cat B can cleave our TNPs and release MMAE to kill GBM cells. The ferumoxytol core enables in vivo drug tracking with magnetic resonance imaging (MRI). We incubated U87-MG GBM cells with TNPs or ferumoxytol and evaluated the TNP content in the cells with transmission electron microscopy and Prussian blue staining. In addition, we stereotaxically implanted 6- to 8-week-old nude mice with U87-MG with U87-MG GBM cells that express a fusion protein of Green Fluorescence Protein and firefly Luciferase (U87-MG/GFP-fLuc). We then treated the animals with an intravenous dose of TNPs (25 mg/kg of ferumoxytol, 0.3 mg/kg of MMAE) or control. We also evaluated the combination of TNP treatment with radiation therapy. We performed MRI before and after TNP injection. We compared the results for tumor and normal brain tissue between the TNP and control groups. We also monitored tumor growth for a period of 21 days.

Results

We successfully synthesized TNPs with a hydrodynamic size of 41 ± 5 nm and a zeta potential of 6 ± 3 mV. TNP-treated cells demonstrated a significantly higher iron content than ferumoxytol-treated cells (98 ± 1% vs. 3 ± 1% of cells were iron-positive, respectively). We also found significantly fewer live attached cells in the TNP-treated group (3.8 ± 2.0 px2) than in the ferumoxytol-treated group (80.0 ± 14.5 px2, p < 0001). In vivo MRI studies demonstrated a decline in the tumor signal after TNP (T2= 28 ms) but not control (T2= 32 ms) injections. When TNP injection was combined with radiation therapy, the tumor signals dropped further (T2 = 24 ms). The combination therapy of radiation therapy and TNPs extended the median survival from 14.5 days for the control group to 45 days for the combination therapy group.

Conclusion

The new cleavable TNPs reported in this work accumulate in GBM, cause tumor cell death, and have synergistic effects with radiation therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaNanoparticlesMiceAnimalsPrecision MedicineFerrosoferric OxidePeptide HydrolasesMice, NudeMagnetic Resonance ImagingEndopeptidasesIronCell Line, Tumor

Stichwörter der Autor:innen

MMAEMRIglioblastomananoparticlestheranostic

Substanzen

Ferrosoferric OxidePeptide HydrolasesEndopeptidasesIron

Autor:innen und Institutionen

  • Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, CA, U.S.A.
  • Stanford Center for Innovation in In vivo Imaging (SCi 3 ) at Porter, Canary Center for Cancer Early Detection, Stanford University, CA, U.S.A.
  • Sarafan Chemistry, Engineering & Medicine for Human Health (Chem-H), Stanford University, Stanford, CA, U.S.A.
  • Stanford Center for Innovation in In vivo Imaging (SCi 3 ) at Clark, James H. Clark Center, Stanford University, CA, U.S.A.

Förderung

  • NICHD NIH HHS

Zitieren

APA

Huang, C. H., Chang, E., Zheng, L., Raj, J. G. J., Wu, W., Pisani, L. J., & Daldrup-Link, H. E. (2023). Tumor protease-activated theranostic nanoparticles for MRI-guided glioblastoma therapy. Theranostics. https://doi.org/10.7150/thno.79342

Vancouver

Huang CH, Chang E, Zheng L, Raj JGJ, Wu W, Pisani LJ, et al. Tumor protease-activated theranostic nanoparticles for MRI-guided glioblastoma therapy. Theranostics. 2023. doi:10.7150/thno.79342

BibTeX
@article{Huang2023,
  author = {Huang, Ching-Hsin and Chang, Edwin and Zheng, Li and Raj, Joe Gerald Jesu and Wu, Wei and Pisani, Laura J and Daldrup-Link, Heike E},
  title = {Tumor protease-activated theranostic nanoparticles for MRI-guided glioblastoma therapy},
  journal = {Theranostics},
  year = {2023},
  doi = {10.7150/thno.79342}
}
Kostenlos starten →